Contineum Therapeutics, Inc. (CTNM) News
Follow Contineum Therapeutics, Inc. (CTNM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Wednesday. Shares of Hewlett Packard Enterprise Co (NYSE: HPE ) rose during Wednesday’s session after the company announced it raised its FY27
LIVE | Sep 30, 2026, 01:55 PM UTC
L
Contineum Therapeutics Price Target Cut to $17.00/Share From $18.00 by Morgan Stanley
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 01:17 PM UTC
L
Contineum Therapeutics Price Target Cut to $24.00/Share From $26.00 by Jones Trading
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 03:28 PM UTC
H
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ: CTNM ) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical up
LIVE | Sep 15, 2026, 03:07 PM UTC
L
US stock indexes swing lower as oil, yields jump
U.S. STOCK INDEXES SWING LOWER AS OIL, YIELDS JUMPWall Street's three main indexes turned lower on Tuesday, with the Dow Industrials DJ:DJI leading losses amid broad pressure from a rally in oil prices and climbing Treas
COMMODITIES | Sep 15, 2026, 02:27 PM UTC
L
Contineum Therapeutics Is Maintained at Outperform by Baird
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:00 PM UTC
L
Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint
By Stephen NakrosisShares of Contineum Therapeutics were trading lower after-hours Monday, following news a Phase 2 trial of an treatment for depression failed to meet its primary efficacy endpoint.Contineum said JNJ-512
EQUITY | Sep 14, 2026, 08:36 PM UTC
L
Contineum Therapeutics: Phase 2 MOONLIGHT-1 of JNJ-5120/PIPE-307 fails primary endpoint; drug well-tolerated
Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 did not meet its primary efficacy endpoint, though the drug was well-tolerated with no new safety signals.Key Highlights:Original SE
REGULATION | Sep 14, 2026, 08:13 PM UTC
L
Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics NASDAQ:CTNM said on Monday an experimental depression drug it developed with Johnson & Johnson NYSE:JNJ failed to meet the main goal of a mid-stage study.
NEWS | Sep 14, 2026, 08:11 PM UTC
L
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significan
NEWS | Sep 14, 2026, 08:05 PM UTC
L
CTNM Contineum Therapeutics to Present at 2026 Morgan Stanley Healthcare Conference
Contineum Therapeutics (CTNM) says it will present at the 2026 Morgan Stanley Global Healthcare Conference.
EQUITY | Aug 25, 2026, 08:06 PM UTC
L
CTNM - Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
CTNM - Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
EQUITY | Jul 30, 2026, 08:11 PM UTC
L
Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist wi
Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) - Blocking LPAR1 inhibits key steps in the fibrosis pathway with p
EQUITY | Jun 30, 2026, 08:08 PM UTC